{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:18:23Z","timestamp":1784290703408,"version":"3.55.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nNon-small cell lung cancer (NSCLC) remains a significant global health concern, with EGFR<\/jats:italic> mutations playing a pivotal role in guiding treatment decisions. This prospective study investigated the prevalence and clinical implications of EGFR<\/jats:italic> mutations in Moroccan NSCLC patients.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nA cohort of 302 NSCLC patients was analyzed for EGFR<\/jats:italic> mutations using multiple techniques. Demographic, clinical, and pathological characteristics were assessed, and overall survival (OS) outcomes were compared among different EGFR<\/jats:italic> mutation subtypes.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nEGFR<\/jats:italic> mutations were present in 23.5% of patients, with common mutations (81.69%) dominating. Common mutations showed strong associations with female gender and non-smoking status, while rare mutations were associated with a positive smoking history. Patients with EGFR<\/jats:italic> mutations receiving tyrosine kinase inhibitors (TKIs) had significantly improved OS compared to wild-type EGFR<\/jats:italic> patients. Notably, patients with common EGFR<\/jats:italic> mutations had the highest OS, while those with rare mutations had a shorter survival period, albeit not statistically significant.<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nThis study highlights the relevance of EGFR<\/jats:italic> mutation status in NSCLC patients, particularly in therapeutic decision-making. The association between smoking history and rare mutations suggests the need for tailored approaches. The survival advantage for patients with common EGFR<\/jats:italic> mutations underscores the significance of personalized treatment strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0298721","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:34:50Z","timestamp":1717608890000},"page":"e0298721","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-3380","authenticated-orcid":true,"given":"Sara","family":"Boukansa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Mouhrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-4555","authenticated-orcid":true,"given":"Fatima","family":"El Agy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"El Bardai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Bouguenouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounia","family":"Serraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Ouadnouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Smahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badreeddine","family":"Alami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawfel","family":"Mellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Benbrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinde","family":"El Fatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"3","key":"pone.0298721.ref001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000484175","article-title":"NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy","volume":"95","author":"D. Kauffmann-Guerrero","year":"2018","journal-title":"Respiration."},{"issue":"3","key":"pone.0298721.ref002","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.lungcan.2011.08.004","article-title":"Trends in incidence of small cell lung cancer and all lung cancer","volume":"75","author":"S. P. Riaz","year":"2012","journal-title":"Lung Cancer"},{"issue":"5676","key":"pone.0298721.ref003","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy","volume":"304","author":"J. G. Paez","year":"2004","journal-title":"Science"},{"issue":"5","key":"pone.0298721.ref004","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2006.07.3585","article-title":"Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer","volume":"25","author":"L. V. Sequist","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"pone.0298721.ref005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.1167.11.3","article-title":"The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non\u2013Small Cell Lung Cancers","volume":"11","author":"M. Tokumo","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"pone.0298721.ref006","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Y. L. Wu","year":"2017","journal-title":"Lancet. Oncol"},{"issue":"10","key":"pone.0298721.ref007","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"T. S. Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"pone.0298721.ref008","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMc1703339","article-title":"Osimertinib in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Y. Yin","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"pone.0298721.ref009","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"M. Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"pone.0298721.ref010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"J.-C. Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"pone.0298721.ref011","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u2018never smokers\u2019 and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"W. Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"pone.0298721.ref012","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications","volume":"13","author":"H. Yasuda","year":"2012","journal-title":"Lancet. Oncol."},{"issue":"21","key":"pone.0298721.ref013","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"T. J. Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"pone.0298721.ref014","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2013.01.018","article-title":"Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance","volume":"80","author":"E. Massarelli","year":"2013","journal-title":"Lung Cancer"},{"issue":"0","key":"pone.0298721.ref015","article-title":"Uncommon EGFR mutations in non-small-cell lung cancer","volume":"5","author":"M. Russano","year":"2022","journal-title":"Precis. Cancer Med."},{"issue":"10","key":"pone.0298721.ref016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108878","article-title":"Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need","volume":"24","author":"G. Pretelli","year":"2023","journal-title":"Int. J. Mol. Sci"},{"issue":"6","key":"pone.0298721.ref017","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.21037\/jtd-21-1924","article-title":"Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort","volume":"14","author":"P. Tankere","year":"2022","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"pone.0298721.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: A double role in lung cancer cell survival?","volume":"4","author":"K. Suda","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"pone.0298721.ref019","doi-asserted-by":"crossref","first-page":"600844","DOI":"10.3389\/fonc.2021.600844","article-title":"Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis","volume":"11","author":"C. Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"pone.0298721.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4108-0","article-title":"The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment","volume":"18","author":"C. Demuth","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"pone.0298721.ref021","first-page":"1","article-title":"EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives","volume":"10","author":"J. Hou","year":"2022","journal-title":"Biomark. Res."},{"issue":"1","key":"pone.0298721.ref022","first-page":"1","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"S. Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther. 2019 41"},{"key":"pone.0298721.ref023","first-page":"1595","article-title":"EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer","volume":"8","author":"S. Fang","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"pone.0298721.ref024","first-page":"192","article-title":"Updated version published 15 September 2020 by the ESMO Guidelines Committee Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up \u2020","volume":"4","author":"D. Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"21","key":"pone.0298721.ref025","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"\u201cBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non \u2010 small-cell lung cancer in Asia (IPASS)","volume":"29","author":"M. Fukuoka","year":"2011","journal-title":"J. Clin. Oncol"},{"issue":"2","key":"pone.0298721.ref026","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial,","volume":"11","author":"T. Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"pone.0298721.ref027","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.bjc.6604068","article-title":"\u2018Classical\u2019 but not \u2018other\u2019 mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer","volume":"97","author":"A. G. Pallis","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"7","key":"pone.0298721.ref028","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"J. C. H. Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"pone.0298721.ref029","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"H. Shigematsu","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"pone.0298721.ref030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"S. V. Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"pone.0298721.ref031","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40880-017-0187-6","article-title":"Proportion and clinical features of never-smokers with non-small cell lung cancer","volume":"36","author":"J. Cho","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"pone.0298721.ref032","article-title":"Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation","volume":"13","author":"H. W. Ko","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"pone.0298721.ref033","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/JTO.0000000000000492","article-title":"Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma","volume":"10","author":"Z. Lohinai","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"pone.0298721.ref034","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \u2018uncommon\u2019 epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"J. Y. Wu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"pone.0298721.ref035","article-title":"Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC)","author":"B. Keam"},{"issue":"1","key":"pone.0298721.ref036","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100934","article-title":"Long term follow-up of EGFR mutated NSCLC cases","volume":"14","author":"G. Rennert","year":"2021","journal-title":"Transl. Oncol."},{"issue":"1","key":"pone.0298721.ref037","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.arbres.2017.07.012","article-title":"Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population","volume":"54","author":"F. Aguiar","year":"2018","journal-title":"Arch. Bronconeumol"},{"key":"pone.0298721.ref038","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.2147\/CMAR.S200126","article-title":"Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma","volume":"11","author":"H. Zheng","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"2","key":"pone.0298721.ref039","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/cncr.27730","article-title":"Association of KRAS and EGFR Mutations with Survival in Patients with Advanced Lung Adenocarcinomas","volume":"119","author":"M. L. Johnson","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"pone.0298721.ref040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/COC.0000000000000282","article-title":"EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients","volume":"41","author":"Y. W. Choi","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"pone.0298721.ref041","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"G. J. Riely","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"pone.0298721.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4283-z","article-title":"Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial","volume":"18","author":"Z. Mark\u00f3czy","year":"2018","journal-title":"BMC Cancer"},{"key":"pone.0298721.ref043","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"P. T. Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"pone.0298721.ref044","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.21037\/jtd-19-3790","article-title":"Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors","volume":"12","author":"A. Brindel","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"pone.0298721.ref045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-023-02768-z","article-title":"Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes","volume":"21","author":"W. Zhao","year":"2023","journal-title":"BMC Med."},{"issue":"6","key":"pone.0298721.ref046","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3390\/ijms20061431","article-title":"Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario","volume":"20","author":"A. Russo","year":"2019","journal-title":"Int. J. Mol. Sci"},{"issue":"10","key":"pone.0298721.ref047","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.21037\/tlcr-22-235","article-title":"Multiple mutations in the EGFR gene in lung cancer: a systematic review","volume":"11","author":"J. P. Casta\u00f1eda-Gonz\u00e1lez","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"issue":"11","key":"pone.0298721.ref048","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/cncr.31329","article-title":"Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas","volume":"124","author":"B. Zhang","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"pone.0298721.ref049","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1097\/JTO.0b013e3181e8b3c5","article-title":"Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer","volume":"5","author":"A. Hata","year":"2010","journal-title":"J. Thorac. Oncol."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:35:41Z","timestamp":1717608941000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298721"}},"subtitle":[],"editor":[{"given":"Rama Krishna","family":"Kancha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0298721","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}